IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Core Insights - IO Biotech announced new pre-clinical data for its cancer vaccine candidates IO112 and IO170 at the Society for Immunotherapy of Cancer's 40th Annual Meeting [1][6] - The company plans to file an Investigational New Drug Application for IO112 in 2026, indicating a commitment to advancing its cancer immunotherapy pipeline [2] Group 1: Vaccine Candidates - IO112, targeting arginase 1 (Arg1), shows robust expansion of Arg1-specific T cells that inhibit tumor growth by reprogramming immune suppressive myeloid cells [3][5] - IO170, targeting Transforming Growth Factor (TGF)-β, activates TGF-β-specific T cells to promote anti-tumor activities, demonstrating significant tumor growth inhibition and reduced lung metastasis [4][5] Group 2: Research and Development - The data presented highlight the unique approach of IO Biotech's T-win® platform, which targets both tumor cells and immune-suppressive cells in the tumor microenvironment [5][8] - The company is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials while developing additional candidates through preclinical stages [8]